Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioengineering
EKR Therapeutics Achieves Key Growth Milestone with the Acquisition of Rights from Pacira Pharmaceuticals to DepoDur, a Novel Extended-Release Opioid Analgesic for Post Operative Pain
August 31st, 2007
EKR Therapeutics, Inc., a specialty pharmaceutical company focused on acquiring, developing, and commercializing proprietary products to enhance patient quality-of-life in the acute care setting, announced it has acquired exclusive marketing and distribution rights to DepoDur(R) (morphine sulfate extended release liposome injection) for the Americas from San Diego-based Pacira Pharmaceuticals, who will continue to manufacture the product. Formerly a business unit of SkyePharma, PLC, Pacira Pharmaceuticals is an independent private company focused on developing and manufacturing controlled-release injectable products based on their DepoFoam(R) and Biosphere(R) drug...
Source: Drug Week (2007-08-31)
|
